The philadelphia chromosome negative chronic myeloproliferative disorders: A practical overview

Mayo Clinic Proceedings

Volumn 73, Issue 12, 1998, Pages 1177-1184

  Tefferi, Ayalew ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BCR ABL PROTEIN; CHLORAMBUCIL; CIMETIDINE; COLESTYRAMINE; DOXEPIN; FLUOXYMESTERONE; HYDROXYUREA; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PHOSPHORUS 32; PREDNISONE;

AGING; ARTICLE; BLEEDING; CHROMOSOME TRANSLOCATION 9; DIARRHEA; EDEMA; FIBROSIS; HEADACHE; HEART PALPITATION; HUMAN; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; ORAL DRUG ADMINISTRATION; PHILADELPHIA 1 CHROMOSOME; PHLEBOTOMY; POLYCYTHEMIA VERA; SPLENECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VERTIGO;

EID: 0031742392     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/73.12.1177     Document Type: Review

References (10)

1. Raskind WH, Fialkow PJ. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 1987;49:127-167
2. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-375
3. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-2663
4. Tefferi A, Silverstein MN, Hoagland HC. Primary thombocythemia. Semin Oncol 1995;22:334-340
5. Cortelazzo S, Finazzi G, Ruggeri M, Vestri 0, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995:332:1132-1136
6. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995:123:656-664
7. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI, editors. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: Saunders; 1995. pp 166-194
8. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier l, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-1018
9. Tefferi A, Elliott MA, Solberg LA Jr, Silverstein MN. New drugs in essential thrombocythemia and polycythemia vera. Blood Rev 1997;ll:l-7
10. Tefferi A, Silverstein MN, Noel P. Agnogenic myeloid metaplasia. Semin Oncol 1995:22:327-333